HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial

The HPV vaccine has shown sustained efficacy and consistent stabilization of antibody levels, even after a single dose. We defined the HPV16-VLP antibody avidity patterns over 11 years among women who received one- or three doses of the bivalent HPV vaccine in the Costa Rica HPV Vaccine Trial. Absol...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsang, Sabrina H., Schiller, John T., Porras, Carolina, Kemp, Troy J., Herrero, Rolando, Schussler, John, Sierra, Monica S., Cortes, Bernal, Hildesheim, Allan, Lowy, Douglas R., Rodríguez, Ana Cecilia, Romero, Byron, Çuburu, Nicolas, Shing, Jaimie Z., Pinto, Ligia A., Sampson, Joshua N., Kreimer, Aimée R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964739/
https://www.ncbi.nlm.nih.gov/pubmed/35351898
http://dx.doi.org/10.1038/s41541-022-00431-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964739/
https://www.ncbi.nlm.nih.gov/pubmed/35351898
http://dx.doi.org/10.1038/s41541-022-00431-x

Ejemplares similares